

Global Gene Therapy Market Report and Forecast 2023-2031

Market Report | 2023-05-06 | 147 pages | EMR Inc.

AVAILABLE LICENSES:

- Single User License \$5999.00
- Five User License \$7999.00
- Corporate License \$9999.00

Report description:

Global Gene Therapy Market Report and Forecast 2023-2031

Global Gene Therapy Market

The global gene therapy market value was USD 6.36 billion in 2022 driven by the increasing prevalence of genetic disorders across the globe. The market size is anticipated to grow at a CAGR of 22.8% during the forecast period of 2023-2031 to achieve a value of USD 40.39 billion by 2031.

Gene Therapy Introduction

Gene therapy is a rapidly evolving field in medical science, offering innovative solutions for the treatment and management of various genetic disorders. It is a ground-breaking approach that involves the direct manipulation of an individual's genes to correct or replace faulty genetic information, ultimately mitigating or curing the associated medical condition. With the advent of advanced molecular biology and genetic engineering techniques, gene therapy has emerged as a promising alternative to traditional treatment methods, aiming to address the root causes of genetic diseases rather than just managing their symptoms. The purpose of this report is to provide an overview of gene therapy, its underlying principles, and its potential applications. We will examine the different types of gene therapy, the methods employed to deliver therapeutic genetic material into target cells, and the safety and ethical concerns associated with this cutting-edge technology. Furthermore, we will explore the latest research and clinical trials that demonstrate the potential of gene therapy in treating a wide range of genetic disorders, including monogenic diseases, metabolic disorders, and certain types of cancer.

By presenting an in-depth analysis of gene therapy, this report aims to offer a comprehensive understanding of its current state and future prospects. With continued research and clinical trials, gene therapy holds immense potential to revolutionize the field of medicine and pave the way for personalized, precision-based treatments that address the unique genetic makeup of each individual patient.

Gene Therapy Market Scenario

The global gene therapy market has experienced substantial growth in recent years, driven by factors such as the increasing prevalence of genetic disorders, advancements in genetic engineering techniques, and a growing number of regulatory approvals for gene therapy products. As of September 2021, the market was projected to continue expanding at a rapid pace, with a

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scott-international.com

www.scott-international.com

compound annual growth rate (CAGR) ranging from 20% to 30% over the next several years.

Factors driving the growth of the gene therapy market included the rising prevalence of genetic disorders, advancements in genetic engineering techniques, and growing investments in research and development.

The gene therapy market faced challenges such as safety concerns, ethical issues, and high costs associated with gene therapy treatments.

Gene Therapy Market segmentations

Market Breakup by Therapy Type

- In-Vivo Therapy
- Ex-Vivo Therapy

Market Breakup by Indications

- Acute Lymphoblastic Leukemia (ALL)
- Inherited Retinal Disease
- Large B-Cell Lymphoma
- ADA-SCID
- Melanoma
- Beta-Thalassemia Major/SCD
- Head & Neck Squamous Cell Carcinoma
- Peripheral Arterial Disease
- Spinal Muscular Atrophy (SMA)
- Others

Market Breakup by Vector Type

- Viral Vector
- Lentiviral Vectors
- Adeno-Associated Viral (Aav) Vectors
- Retrovirus Vectors
- Modified Herpes Simplex Virus
- Adenovirus Vectors
- Others
- Non-Viral Vector

Market Breakup by Region

- North America
- United States of America
- Canada
- Europe
- United Kingdom
- Germany
- France
- Italy
- Others
- Asia Pacific
- China
- Japan

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- India
- ASEAN
- Australia
- Others
- Latin America
- Brazil
- Argentina
- Mexico
- Others
- Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Nigeria
- South Africa
- Others

Key Trends in the Gene Therapy Market

Some key trends of the market are as follows:

- Regulatory Approvals: The increasing number of regulatory approvals for gene therapy products has been a significant trend, as it indicates the growing recognition and acceptance of these treatments by regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
- Strategic Collaborations and Partnerships: Companies and research institutions have been forming collaborations and partnerships to share resources, knowledge, and expertise. These collaborations aim to accelerate the development of gene therapy products, expand their pipelines, and enhance their market presence.
- Personalized Medicine: The gene therapy market has been increasingly focusing on personalized medicine, as it offers the potential to provide targeted and precise treatments based on an individual's unique genetic makeup. This approach is expected to improve treatment outcomes and reduce the risk of side effects.
- Advancements in Delivery Systems: Continued research and development have led to the emergence of new and more efficient gene delivery systems, such as viral and non-viral vectors, which play a crucial role in the success of gene therapy treatments.
- Focus on Rare Diseases: Many gene therapy companies have been concentrating on developing treatments for rare genetic diseases, often with limited treatment options. This focus has been driven by the high unmet medical needs, the potential for orphan drug designation, and the possibility of premium pricing for successful therapies.
- Expansion of Indications: Gene therapy was initially focused on monogenic diseases; however, its potential applications have expanded to include a wider range of conditions, such as various forms of cancer, neurological disorders, and metabolic diseases.
- Government and Private Funding: The gene therapy market has witnessed increased financial support from both government and private organizations. This funding has accelerated research and development, clinical trials, and commercialization of gene therapy products.
- Ethical and Regulatory Discussions: As gene therapy continues to advance, ethical and regulatory discussions surrounding its use have become more prominent. This includes topics such as germline editing, access to treatments, and the long-term safety of gene therapies.

Gene Therapy Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

- AstraZeneca
- Boehringer Ingelheim International GmbH
- GlaxoSmithKline plc
- Novartis AG

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- [] CHIESI Farmaceutici SpA
- [] Sunovion Pharmaceuticals Inc
- [] Teva Pharmaceutical Industries Ltd
- [] Mylan N.V., Orion Corporation
- [] Merck & Co., Inc.
- [] Grifols, S.A.
- [] Abbott
- [] F. Hoffmann-La Roche Ltd
- [] Vectura Group plc
- [] Pfizer Inc, Alkermes
- [] Mylan N.V, Almirall, S.A, Genentech, Inc
- [] Biogen
- [] Astellas Pharma Inc.

Table of Contents:

- 1 Preface
 - 1.1 Objectives of the Study
 - 1.2 Key Assumptions
 - 1.3 Report Coverage - Key Segmentation and Scope
 - 1.4 Research Methodology
- 2 Executive Summary
- 3 Global Gene Therapy Market Overview
 - 3.1 Global Gene Therapy Market Historical Value (2016-2022)
 - 3.2 Global Gene Therapy Market Forecast Value (2023-2031)
- 4 Global Gene Therapy Market Landscape
 - 4.1 Global Gene Therapy Developers Landscape
 - 4.1.1 Analysis by Year of Establishment
 - 4.1.2 Analysis by Company Size
 - 4.1.3 Analysis by Region
 - 4.2 Global Gene Therapy Product Landscape
 - 4.2.1 Analysis by Therapy Type
 - 4.2.2 Analysis by Vector Type
 - 4.2.3 Analysis by Indications
- 5 Global Gene Therapy Market Dynamics
 - 5.1 Market Drivers and Constraints
 - 5.2 SWOT Analysis
 - 5.3 Porter's Five Forces Model
 - 5.4 Key Demand Indicators
 - 5.5 Key Price Indicators
 - 5.6 Industry Events, Initiatives, and Trends
 - 5.7 Value Chain Analysis
- 6 Global Gene Therapy Market Segmentation
 - 6.1 Global Gene Therapy Market by Therapy Type
 - 6.1.1 Market Overview
 - 6.1.2 In-Vivo Therapy
 - 6.1.3 Ex-Vivo Therapy

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 6.2 Global Gene Therapy Market by Indications
 - 6.2.1 Market Overview
 - 6.2.2 Acute Lymphoblastic Leukemia (ALL)
 - 6.2.3 Inherited Retinal Disease
 - 6.2.4 Large B-Cell Lymphoma
 - 6.2.5 ADA-SCID
 - 6.2.6 Melanoma
 - 6.2.7 Beta-Thalassemia Major/SCD
 - 6.2.8 Head & Neck Squamous Cell Carcinoma
 - 6.2.9 Peripheral Arterial Disease
 - 6.2.10 Spinal Muscular Atrophy (SMA)
 - 6.2.11 Others
- 6.3 Global Gene Therapy Market by Vector Type
 - 6.3.1 Market Overview
 - 6.3.2 Viral Vector
 - 6.3.2.1 Lentiviral Vectors
 - 6.3.2.2 Adeno-Associated Viral (Aav) Vectors
 - 6.3.2.3 Retrovirus Vectors
 - 6.3.2.4 Modified Herpes Simplex Virus
 - 6.3.2.5 Adenovirus Vectors
 - 6.3.2.6 Others
 - 6.3.3 Non-Viral Vector
- 6.4 Global Gene Therapy Market by Region
 - 6.4.1 Market Overview
 - 6.4.2 North America
 - 6.4.3 Europe
 - 6.4.4 Asia Pacific
 - 6.4.5 Latin America
 - 6.4.6 Middle East and Africa
- 7 North America Gene Therapy Market
 - 7.1 Market Share by Country
 - 7.2 United States of America
 - 7.3 Canada
- 8 Europe Gene Therapy Market
 - 8.1 Market Share by Country
 - 8.2 United Kingdom
 - 8.3 Germany
 - 8.4 France
 - 8.5 Italy
 - 8.6 Others
- 9 Asia Pacific Gene Therapy Market
 - 9.1 Market Share by Country
 - 9.2 China
 - 9.3 Japan
 - 9.4 India
 - 9.5 ASEAN
 - 9.6 Australia

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 9.7 Others
- 10 Latin America Gene Therapy Market
 - 10.1 Market Share by Country
 - 10.2 Brazil
 - 10.3 Argentina
 - 10.4 Mexico
 - 10.5 Others
- 11 Middle East and Africa Gene Therapy Market
 - 11.1 Market Share by Country
 - 11.2 Saudi Arabia
 - 11.3 United Arab Emirates
 - 11.4 Nigeria
 - 11.5 South Africa
 - 11.6 Others
- 12 Patent Analysis
 - 12.1 Analysis by Type of Patent
 - 12.2 Analysis by Publication year
 - 12.3 Analysis by Issuing Authority
 - 12.4 Analysis by Patent Age
 - 12.5 Analysis by CPC Analysis
 - 12.6 Analysis by Patent Valuation
 - 12.7 Analysis by Key Players
- 13 Grants Analysis
 - 13.1 Analysis by Year
 - 13.2 Analysis by Amount Awarded
 - 13.3 Analysis by Issuing Authority
 - 13.4 Analysis by Grant Application
 - 13.5 Analysis by Funding Institute
 - 13.6 Analysis by NIH Departments
 - 13.7 Analysis by Recipient Organization
- 14 Clinical Trials Analysis
 - 14.1 Analysis by Trial Registration Year
 - 14.2 Analysis by Trial Status
 - 14.3 Analysis by Trial Phase
 - 14.4 Analysis by Therapeutic Area
 - 14.5 Analysis by Geography
- 15 Funding Analysis
 - 15.1 Analysis by Type of Funding
 - 15.2 Analysis by Funding Amount
 - 15.3 Analysis by Leading Players
 - 15.4 Analysis by Leading Investors
 - 15.5 Analysis by Geography
- 16 Partnership and Collaborations Analysis
 - 16.1 Analysis by Partnership Instances
 - 16.2 Analysis by Type of Partnership
 - 16.3 Analysis by Leading Players
 - 16.4 Analysis by Geography

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 17 Regulatory Framework
 - 17.1 Regulatory Overview
 - 17.1.1 US FDA
 - 17.1.2 EU EMA
 - 17.1.3 INDIA CDSCO
 - 17.1.4 JAPAN PMDA
 - 17.1.5 Others
- 18 Supplier Landscape
 - 18.1 AstraZeneca
 - 18.1.1 Financial Analysis
 - 18.1.2 Product Portfolio
 - 18.1.3 Demographic Reach and Achievements
 - 18.1.4 Mergers and Acquisitions
 - 18.1.5 Certifications
 - 18.2 Boehringer Ingelheim International GmbH
 - 18.2.1 Financial Analysis
 - 18.2.2 Product Portfolio
 - 18.2.3 Demographic Reach and Achievements
 - 18.2.4 Mergers and Acquisitions
 - 18.2.5 Certifications
 - 18.3 GlaxoSmithKline plc
 - 18.3.1 Financial Analysis
 - 18.3.2 Product Portfolio
 - 18.3.3 Demographic Reach and Achievements
 - 18.3.4 Mergers and Acquisitions
 - 18.3.5 Certifications
 - 18.4 Novartis AG
 - 18.4.1 Financial Analysis
 - 18.4.2 Product Portfolio
 - 18.4.3 Demographic Reach and Achievements
 - 18.4.4 Mergers and Acquisitions
 - 18.4.5 Certifications
 - 18.5 CHIESI Farmaceutici SpA
 - 18.5.1 Financial Analysis
 - 18.5.2 Product Portfolio
 - 18.5.3 Demographic Reach and Achievements
 - 18.5.4 Mergers and Acquisitions
 - 18.5.5 Certifications
 - 18.6 Sunovion Pharmaceuticals Inc
 - 18.6.1 Financial Analysis
 - 18.6.2 Product Portfolio
 - 18.6.3 Demographic Reach and Achievements
 - 18.6.4 Mergers and Acquisitions
 - 18.6.5 Certifications
 - 18.7 Teva Pharmaceutical Industries Ltd
 - 18.7.1 Financial Analysis
 - 18.7.2 Product Portfolio

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 18.7.3 Demographic Reach and Achievements
- 18.7.4 Mergers and Acquisitions
- 18.8 Mylan N.V., Orion Corporation
 - 18.8.1 Financial Analysis
 - 18.8.2 Product Portfolio
 - 18.8.3 Demographic Reach and Achievements
 - 18.8.4 Mergers and Acquisitions
 - 18.8.5 Certifications
- 18.9 Merck & Co., Inc.
 - 18.9.1 Financial Analysis
 - 18.9.2 Product Portfolio
 - 18.9.3 Demographic Reach and Achievements
 - 18.9.4 Mergers and Acquisitions
 - 18.9.5 Certifications
- 18.10 Grifols, S.A.
 - 18.10.1 Financial Analysis
 - 18.10.2 Product Portfolio
 - 18.10.3 Demographic Reach and Achievements
 - 18.10.4 Mergers and Acquisitions
 - 18.10.5 Certifications
- 18.11 Abbott
 - 18.11.1 Financial Analysis
 - 18.11.2 Product Portfolio
 - 18.11.3 Demographic Reach and Achievements
 - 18.11.4 Mergers and Acquisitions
 - 18.11.5 Certifications
- 18.12 F. Hoffmann-La Roche Ltd
 - 18.12.1 Financial Analysis
 - 18.12.2 Product Portfolio
 - 18.12.3 Demographic Reach and Achievements
 - 18.12.4 Mergers and Acquisitions
 - 18.12.5 Certifications
- 18.13 Vectura Group plc
 - 18.13.1 Financial Analysis
 - 18.13.2 Product Portfolio
 - 18.13.3 Demographic Reach and Achievements
 - 18.13.4 Mergers and Acquisitions
 - 18.13.5 Certifications
- 18.14 Pfizer Inc, Alkermes
 - 18.14.1 Financial Analysis
 - 18.14.2 Product Portfolio
 - 18.14.3 Demographic Reach and Achievements
 - 18.14.4 Mergers and Acquisitions
 - 18.14.5 Certifications
- 18.15 Mylan N.V, Almirall, S.A, Genentech, Inc
 - 18.15.1 Financial Analysis
 - 18.15.2 Product Portfolio

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 18.15.3 Demographic Reach and Achievements
- 18.15.4 Mergers and Acquisitions
- 18.15.5 Certifications
- 18.16 Biogen
 - 18.16.1 Financial Analysis
 - 18.16.2 Product Portfolio
 - 18.16.3 Demographic Reach and Achievements
 - 18.16.4 Mergers and Acquisitions
 - 18.16.5 Certifications
- 18.17 Astellas Pharma Inc.
 - 18.17.1 Financial Analysis
 - 18.17.2 Product Portfolio
 - 18.17.3 Demographic Reach and Achievements
 - 18.17.4 Mergers and Acquisitions
 - 18.17.5 Certifications
- 19 Global Gene Therapy Market- Distribution Model (Additional Insight)
 - 19.1 Overview
 - 19.2 Potential Distributors
 - 19.3 Key Parameters for Distribution Partner Assessment
- 20 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 21 Company Competitiveness Analysis (Additional Insight)
 - 21.1 Very Small Companies
 - 21.2 Small Companies
 - 21.3 Mid-Sized Companies
 - 21.4 Large Companies
 - 21.5 Very Large Companies
- 22 Payment Methods (Additional Insight)
 - 22.1 Government Funded
 - 22.2 Private Insurance
 - 22.3 Out-of-Pocket

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Global Gene Therapy Market Report and Forecast 2023-2031

Market Report | 2023-05-06 | 147 pages | EMR Inc.

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scottss-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$5999.00
	Five User License	\$7999.00
	Corporate License	\$9999.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scottss-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-03-02"/>
		Signature	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scottss-international.com

www.scottss-international.com